Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antiviral therapeutics - Cocrystal Pharma/Kansas State University Research Foundation

Drug Profile

Research programme: antiviral therapeutics - Cocrystal Pharma/Kansas State University Research Foundation

Latest Information Update: 27 Apr 2020

At a glance

  • Originator Kansas state university research foundation
  • Developer Cocrystal Pharma Inc; Kansas state university research foundation
  • Class Antivirals; Small molecules
  • Mechanism of Action Virus replication modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical COVID 2019 infections
  • Research Norovirus infections

Most Recent Events

  • 14 May 2020 Cocrystal Pharma plans to select a lead preclinical molecule from the COVID-19 coronavirus programme in the fourth quarter of 2020
  • 22 Apr 2020 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by Cocrystals
  • 01 Apr 2020 Preclinical trials in COVID-2019 infections in USA (unspecified route), before April 2020

Development Overview

Introduction

Small-molecule, broad spectrum, antiviral compounds are being developed by Cocrystal Pharma (in-licensed from Kansas state university research foundation) for the treatment of Norovirus and COVID-2019 infections. Cocrystal Pharma utilises a structure-based drug discovery technology which provides a 3D structure of inhibitor complexes at near-atomic resolution. This provides immediate insight to structure-activity relationships (SAR) resulting in identification of novel binding sites. Rapid turnaround of structural information is thus possible through highly automated X-ray data processing and refinement. By utilizing this technology, Cocrystal is able to develop compounds that specifically target enzymes that are important to viral replication. Preclinical development for COVID-2019 infections and early research for the treatment of norovirus is underway in the US.

Cocrystal Pharma is seeking opportunities for collaborations for the advancement of the programme [1] .

Company Agreements

In April 2020, Cocrystal pharma expanded its licensing agreement with Kansas State University Research Foundation to include rights to additional preclinical leads and to develop broad-spectrum antiviral compounds for the treatment of COVID-2019 infections.
Earlier in March 2020, Cocrystal pharma acquired the patent rights from Kansas State University Research Foundation. Both the companies had entered into a licensing agreement with Kansas State University Research Foundation (KSURF) in February 2020, for the development of antiviral compounds for the treatment of Norovirus and COVID-2019 infections. Under this agreement, Cocrystal will receive exclusive, royalty-bearing right and license to antiviral compounds for humans covered by KSURF’s patents. Cocrystal intends to pursue preclinical and clinical development of theses antiviral compounds. Cocrystal will further advance its antiviral programs significantly by providing potent compounds for further development. [2] [1] [3]

Key Development Milestones

In May 2020, Cocrystal Pharma reported that the additional compounds licensed from Kansas state university research foundation (KSURF) demonstrated in vitro and in vivo activity in animal models against the viral pathogens causing MERS and SARS, coronaviruses. Cocrystal initiated preclinical studies of COVID-19 inhibitors received from KSURF during quarter two of 2020 [4] [5] .

As of May 2020, Cocrystal Pharma reported that it plans to identify additional inhibitors using its proprietary platform technology in second and the third quarter of 2020. The company also plans to identify additional inhibitors from internal sources using its proprietary platform technology in quarter three of 2020 and anticipates the selection of its lead preclinical molecule in quarter four of 2020 [4] [5] .

In April 2020, Cocrystal released pharmacodynamics data from preclinical study of antiviral therapeutics for COVID-2019 infections [3] .

Early research for Norovirus infections is underway in the US [2]

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals, Small molecules
  • Target Virus replication
  • Mechanism of Action Virus replication modulators
  • WHO ATC code

    J05A-X (Other antivirals)

  • EPhMRA code

    J5B9 (Antivirals, others)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Preclinical USA unspecified / unspecified Cocrystal Pharma Inc, Kansas state university research foundation 01 Apr 2020
Norovirus infections - - Research USA unspecified / unspecified Cocrystal Pharma Inc, Kansas state university research foundation 25 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Kansas state university research foundation Originator USA
Kansas state university research foundation Owner USA
Cocrystal Pharma Inc Licensee USA

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Cocrystal Pharma Inc - Unspecified - 06 Mar 2020

Scientific Summary

Pharmacodynamics

Summary

In preclinical study, administration of antiviral compounds demonstrated significant increase in survival and reduced lung virus titer in the infected animals even when given one day after virus infection [3] .

Future Events

Expected Date Event Type Description Updated
31 Dec 2020 Trial Update Cocrystal pharma plans to initiate preclinical studies for COVID-19 infections in the second half of 2020 [6] 20 May 2020
31 Dec 2020 Trial Update Cocrystal Pharma plans to select a lead preclinical molecule from the COVID-19 coronavirus programme in the fourth quarter of 2020 [4] 20 May 2020
30 Jun 2020 Regulatory Status Cocrystal Pharma intends to file patent application for COVID-2019 infections and Norovirus infections in the second quarter of 2020 [6] 06 Apr 2020
30 Jun 2020 Trial Update Cocrystal Pharma plans to select a lead preclinical molecule from the Noravirus programme in the second quarter of 2020 [6] 20 May 2020

Development History

Event Date Update Type Comment
14 May 2020 Trial Update Cocrystal Pharma plans to select a lead preclinical molecule from the COVID-19 coronavirus programme in the fourth quarter of 2020 [4] Updated 20 May 2020
22 Apr 2020 Scientific Update Pharmacodynamics data from a preclinical study in COVID-2019 infections released by Cocrystals [3] Updated 27 Apr 2020
01 Apr 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections in USA (unspecified route), before April 2020 [3] Updated 27 Apr 2020
30 Mar 2020 Trial Update Cocrystal Pharma plans to select a lead preclinical molecule from the Noravirus programme in the second quarter of 2020 [6] Updated 20 May 2020
30 Mar 2020 Trial Update Cocrystal pharma plans to initiate preclinical studies for COVID-19 infections in the second half of 2020 [6] Updated 20 May 2020
30 Mar 2020 Regulatory Status Cocrystal Pharma intends to file patent application for COVID-2019 infections and Norovirus infections in the second quarter of 2020 [6] Updated 06 Apr 2020
11 Mar 2020 Licensing Status Antiviral therapeutics is available for licensing as of 06 Mar 2020 [1] Updated 24 Mar 2020
06 Mar 2020 Licensing Status Cocrystal Pharma acquired the patent rights from Kansas state university research foundation [1] Updated 24 Mar 2020
06 Mar 2020 Trial Update Cocrystal Pharma plans a preclinical and clinical trial in COVID-2019 infections and Norovirus infections [1] Updated 24 Mar 2020
25 Feb 2020 Licensing Status Cocrystal Pharma in-licenses antiviral compounds from Kansas State University Research Foundation [2] Updated 24 Mar 2020
25 Feb 2020 Phase Change Early research in COVID-2019-infections in USA (unspecified route) [2] Updated 24 Mar 2020
25 Feb 2020 Phase Change Early research in Norovirus infections in USA (unspecified route) [2] Updated 24 Mar 2020

References

  1. Cocrystal Pharma Announces Plans to Advance Coronavirus Program.

    Media Release
  2. Cocrystal Pharma, Inc. Announces License Agreement with Kansas State University Research Foundation for Norovirus and Coronavirus Antiviral Compounds.

    Media Release
  3. Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action.

    Media Release
  4. Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs.

    Media Release
  5. Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs.

    Media Release
  6. Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020.

    Media Release
Back to top